Explain Voriconazole

It has a spectrum of activity similar  to itraconazole but appears to be more active against Aspergillus spp. And some species of  Candida, containing  C. glabrata and  C. krusei. Unlike itraconazole, voriconazole is active against Fusarium spp. Zygomycetes, such as Mucor spp. and Rhizomucor spp., are generally resistant to voriconazole, and infection with these organisms has developed during treatment with the drug.

Voriconazole is FDA-approved for treatment of invasive aspergillosis and esophageal candidiasis, and for treatment of refractory infections caused by  Scedosporium apiospermum and  Fusarium spp.  It is also shown for treatment of candidemia in non-neutropenic patients and for disseminated Candida infections containing the skin, abdomen, bladder and kidney.